AVAI BIO, INC. reported a fiscal 2026 net loss of $(1.75M) on no revenue, compared with a net loss of $(1.14M) and no revenue in fiscal 2025; diluted loss per share was $(0.01) in both years.
Financial Highlights
- Revenue was $0 for FY 2026 and $0 for FY 2025 (company did not generate revenue in either year).
- Net income was a loss of $(1.75M) for FY 2026 versus a loss of $(1.14M) for FY 2025; change in loss $(0.61M), a 53% increase in the loss.
- Diluted earnings per share was $(0.01) for FY 2026 and $(0.01) for FY 2025 (basic and diluted).
Business Highlights
- The company has pivoted to AI and IT services, acquiring Avant! AI, InstantFAME and Wired4Health technology assets to assemble full‑stack AI solutions.
- Operations remain pre‑revenue while AVAI BIO builds product and service capabilities, integrating technologies for unsupervised and supervised learning pipelines and cloud services.
- Management is positioning the firm as an AI‑native expert targeting enterprise AI engagements and has expanded consulting, marketing and R&D activities despite constrained cash and ongoing capital‑raising plans.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.